Zenebou Sylla,

Zenebou Sylla is a journalist who has written for Yahoo News. Her work is characterized by a high level of accuracy and objectivity, with no significant biases, contradictions, or conflicts of interest identified in her reporting. Her articles are generally well-written and easy to read.

99%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author is known for its high journalistic standards. The author strives to maintain neutrality and transparency in its reporting, and avoids conflicts of interest. The author has a reputation for accuracy and rarely gets contradicted on major discrepancies in its reporting.

Bias

100%

Examples:

No current examples available.

Conflicts of Interest

100%

Examples:

No current examples available.

Contradictions

100%

Examples:

No current examples available.

Deceptions

100%

Examples:

No current examples available.

Recent Articles

Justin Mohn Charged with Beheading Father in Pennsylvania

Justin Mohn Charged with Beheading Father in Pennsylvania

Broke On: Wednesday, 31 January 2024 A man named Michael Mohn was brutally murdered in Pennsylvania by his son Justin, who beheaded him and posted a video of the crime on YouTube. The victim's wife discovered her husband decapitated and covered in blood when she returned home from work.

Salem Hospital Faces Class-Action Lawsuit Over Potential HIV, Hepatitis Exposure

Broke On: Saturday, 18 November 2023 Salem Hospital potentially exposed hundreds of patients to HIV or hepatitis due to negligent administration of intravenous medications. The hospital has stated that the risk of infection is very low and no infections have been identified. A class-action lawsuit has been filed against the hospital and its parent company, Mass General Brigham.